BSEResult5d ago · 14 Nov 2026, 06:57 pm

Results for Q and half year ended 30th sept 2026

Sandu Pharmaceuticals Ltd · 524703

✦ AI Summary▲ PositiveResults

Sandu Pharmaceuticals Ltd announced its unaudited financial results for the quarter and half year ended 30th September 2026, with a profit before exceptional items and tax of ₹8591, a net profit for the period of ₹853, and a total comprehensive income for the period of ₹9223. The company's standalone balance sheet as at 30th September 2026 showed total assets of ₹5717.57 lakhs and total liabilities of ₹5717.67 lakhs.

Analysis Scores

Earnings Impact8/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Sandu Pharmaceuticals Ltd - 524703 - Financial Results For Q And Half Year Ended 30Th Sept 2026

Attachments (1)

📄

6051d675-3aac-4020-a3f8-165324181d10.pdf

pdf

Download →
View document text
4% __ SANDU PHARMACEUTICALS LIMITED CIN:L24233GA1985PLC001587 SAP/DU m Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511. Tel: +918 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in Ref: SPL/CORP-SEC/2026-27/BSE/510 Dated:14.11.2026 Bombay Stock Exchange Ltd, Phirojshah Jeejobhoy Towers, 25t Floor, Dalal Street, Mumbai 400 001 Manager-Department of Corporate affairs Sir, Sub: Outcome of the Board Meeting held on 14th November 2026 with Scrip Code 524703. Ref: Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015 A Meeting of the Board of Directors of the Company duly convened on Saturday, 14t November 2026 at 04:00 p.m. and concluded at 6.40p.m. discussed the following business: Approval of Unaudited Financial Results for the quarter and half year ended 30h September. 2026. The Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2026 prepared in compliance with Ind-AS and the Limited Review Report issued by M/s Dave & Dave Chartered Accountants, Mumbai, [Firm Registration. No. 102163W], Statutory Auditors of the Company pursuant to Regulation 33 of Chapter IV of SEBI (Listing Obligations & Disclosure Requirements) Regulations ,2015 have been reviewed by the Audit Committee and placed before the Board of Directors of the Company in their meeting held today ON 14TH November 2026. The same are approved and taken on record by the Board. The Unaudited Financial Results for the quarter and half year ended 30th September 2026 and the Limited Review Report are also available in the website of the company at www.sandu.in and are enclosed herewith for your kind perusal. For Sandu Pharmaceuticals Limited Pratika Mhambray Company Secretary & Compliance Officer ACS :36512 AN ISO 9001:2015 CERTIFIED ORGANISATION Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071. Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in SANDU PHARMACEUTICALS LTD Corporate Office: Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai ~ 400 071. Tel: +9122 2528 4402 / 6920 4400, E-mail: info@sandu.in, Web:www.sandu.in - - (Rsintabhs) 3 Months ended Half Yearly Year ended Particulars Note No. e — | 30th Sept 2026 | 30th June 2026 | 30th Sept 2025 | 30th Sept 2026 | 30th Sept 2025 "“z:::“" | Unaudited | Unaudited | _Unaudited | Unaudited | Audited [TINcomE Revenue From Operations 1 194288 16388 3s8176) 23201 659305 Other Income 1 371 174 1044 656 4 Total income. 195159) 164051 3592.29] 3a38.58] 703739 EXPENSES 2 - Cost of materialy cansurmed g 2 15908 391 135.94) 110118 Purchaof sSteocsk. in-Trade 2 s \ . 98547 4659 1648.07] | coanges in inventories offiished goods,tockin - 2 Trade and workin-progress 2259 . 2026 333.09 40735 Employee benefits expense z 2013 51957 530,15 106908 Finance costs u 260 5.59) 525 112 Depreciation and amortiation expense 3 1655 1637 1657 3292 3453 7.9 Other expenses s o911 5L 57942 133089 1047.35 usucl Total xpenses 18656 160457 347024 LR GaxL| Profi/(loss) before exceptional tems and tax 8591 3605 714 12197] 10532 26554 Exceptionaiems/ Prior Period Adustment 00 | pRoFT/1L05S) BEFORE TAX w531] 605, 718 217 10532 g| fres % Carrent tax 204 5.7 2971 2977| 2939 s Deferred tar 10y 354 54 pit 117 104 Short/ (Excess ax Provision 0o oo 0 1l ) o0 Y | eror (oss) FoR THe PeRioD 853 na 5243 10138 7478 51| OTHER COMPREHENSIVE INCOME terms that wili o be recassified o proft o oss in Subseauent periods [kemeasurement gains/(osses) on post employment defned] lbenefit pans ) 0 oo :] u:l e ) et ! income tax relatng to tems that wil not be recassified to profitorloss 203 23 224 a9 15 1638 ‘TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX) 1370 1552 1348 . 22| TOTAL COMPRIENCOHME EFORN THSE PEIRIOVD (ENET| OF TAX) 9223 38.35] 631 24295 Paid p Equity Capital 966.10] 966.10) %6619 965.10] 966.19) (Face Value of Rs 10/- Per 3har)€ il EARNINGPESR EQUITY SHARE ” Basc os 037, osa 108 o7 18 Oluted 081 037, o84, 105] 077, 183/ For Sandu Pharmaceuticals Lt Dated: 24th Nov 2026 DIN:- 10245195 flegd, Offa & Factry. PoiNos. 25,26, 29 & 30, Pl Industal Estaté Pllame, Marr, Saliao, Bardez Goa - 403511, Tl 491 832 6715000/ 05 /36 / 2407475, E-masla ndupharma@sandiuin c 3 | CIN:L24233GA1985PLCOD1SET i ] 3 c 3~ _ SANDU PHARMACEUTICALS LTD SANDU Corporate offco: Sandu Nagar, 0. K. Sandu Marg, Chembur, Mumbai ~ 400 071. Tasres Tel.: +91 22 2526 4402 / 6920 4400, E-mal: Info@sandu.in, Web: www.sanduin SPAHNDAU RAMACEUTICLIAMILTESD. Standalone Bulance Sheet as at 30th Sept, 2026 B (Rs in lakhs) i As at 30th Sept 2026 As at 31st March, PARTICULARS a2 Amount () Amount () ASSETS Non-current assets Property, Plant and Equipment 848.22} 868.47) Right of use assets 930.35) 942.13| Capital Work in Progress 10.91f 6.41) Other Intangible Assets 1.85] 1.86 Financial Assets Investments 124231 1229.80| Other Financial Asset 00| 3.08) Other Non-Current Assets -~ 12,44 3.24| 3046.09| © 3054.99| Current assets. Inventories - 1133.48] 1047.13] Financial Assets Trade receivables 783.04) 541.09] Cash and cash equivalents 314.27| 590.77| Bank balances other than 9 (a) above. 83.72] 94.82) Other current assets 357.08] 258.11f 2671.59) 2531.94) 5717.57 5586.93| EQUITY AND LIABILITIES Equity = Equity Share capital 966.10| 966.10| Other Equity 3435.20| 3401.23| 4401.30| 4367.33| Non-current liabilities Financial Liabilities Finance Lease obligations 30.86| 30.95) Deferred tax liabilities (Net) 141.63| 146.44] 172.49| 177.39, Current liabilities Financial Liabilities Finance Lease obligations 6.43) Trade payables Due to : 24 Micro and Small Enterprises 60.26) 61.72] Other than Miero and Small Enterprises 478.27| 385.03 Otber Financial Liabilities 39.75) 31.27| Other current liabilities 132.07| 206.59 Pro 42713 346.63) 1143.88| 1042.21 5717.67] 5586.93 For Sandu Pharmaceuticals Ltd Balram Viswanathan Place - Mumbal Managing Director Dated : 14th Nov 2026 -, DIN :- 10245195 1 Regd. Offce & Factory : Pot Nos. 25, 25, 29 & 30, Pheme Industnal Estate, Pllema, Mama, Salgao, Bardez, Goa- 40351| fi“ ] Tel: +91 832 671505/036 0/ 240074/75, E-mak: sandupharma@sandu.in ! CIlkL24239GA1935PLE001567 3~ SANDU PHARMACEUTICALS LTD SAs I ‘/DU Corporate Office: Sandu Nagar, D. K. Sandu Marg, Ghembur, Mumb-a 40l0 071. xvsren v avarveon Tel: +91 22 2528 4402/ 6920 4400, E-mall: info@sandu,in, Web: www.sanduin SANDU PHARMACEUTICALS LIMITED Standalone Statement of Cash Flow for the period ended 30th Sept, 2026 541 (RsIn lakhs) “As a1 301h Sept 2026 As at 315t Mareh, 2026 Particulars. Amoun(t) | Amoun(t§) | Amoun(t€ | Amown(t) A, Cash flow from operating activities Net Profit/ (Loss) before extraordinary itoms and tax il Gaicn Adjustments for: Dopreciation and amortisation expenses e H Finance costs 559 1124 Interest income 1044 = Otter Income ol 7 AL los ls o wo an n cS eal e fo o rf d I on uv be is ft um l e dn et b ti sn /S eu xb ps ei cd ta er dy cS ra en did tu lP oh sy st eo sc -e u tt ri ac dea l rs e cP e iL vt ad b le 4000 4| b4 REq eu -i mt ey asI un rs etr mu em ne tn t gs a it nh sr /o lu og sh se O st ohe nr c C mo pm lp or ye eh ee dn es fi iv nee d I bn ec nom ie t plans o) : 5;1 1 32,10 1297 Operating profit/ (loss) before changes i operating assets & Habilities a4 08 2934 C (ih na cn eeg ae ses ) i !n d o ep ce rr eaa st ei n ig n a is ns ve ets n oris i 634 i eL ((i in nc cr re ea as se e) ) // d de ec cr re ea as se e i in n oT tr ha ed re o r pe ec re ai lv ia nb gl e ss s sefs - 12 005 8. 198 7) Changes in operating liabilities (increase) / decrease in Irade payables 91.77| 203 (increase) / decrease in other operating liabilities 15.99) 3274 1384 291.30) Cash Generated from operation -178.67) Sie0 Income Tax Paid 2131 7498 Net Cash flow from Operating activites -209.98] 61158 B. Cash flow from investing activities Purchases of Praperty, Plant and Equipment 539 7200 Proceeds from Matusity of Fixed Deposits placed with Banks 14.19] 70 [Showing first 8,000 characters — download PDF for full document]